Background and Objectives: Inborn errors of immunity are increasingly diagnosed in developing countries. Immunoglobulin replacement therapy (IGRT) remains the cornerstone of treatment in these patients, and its monitoring has gained importance for optimizing outcomes. We conducted a retrospective study to evaluate the relationship between IgG trough levels and infections in adults with inborn errors of immunity receiving IGRT. Materials and Methods: Adults diagnosed with primary immunodeficiency and receiving IGRT for at least six months were included. Serum IgG trough levels were measured, and infections during follow-up were systematically recorded. Results: A total of 31 adult patients (CVID: 29, XLA: 2) were analyzed. The mean follow-up was 13 months, with a mean serum IgG trough level of 815.8 ± 205.9 mg/dL, achieved with an average IGRT dose of 498.8 ± 93.0 mg/kg/month. Dose adjustments were made in 35.5% of patients, mostly due to weight changes and clinical indications. Overall, 74.2% of patients had at least one infection requiring antibiotics. Patients with mean IgG trough levels below 850 mg/dL had significantly higher rates of antibiotic-requiring infections (p = 0.032, Mann–Whitney U; mean difference = 0.109, 95% CI: 0.037–0.182; p = 0.005 via t-test). Multivariate regression confirmed that lower IgG trough levels were independently associated with higher antibiotic-requiring infection rates (B = −0.024, 95% CI: −0.045 to −0.002, p = 0.033), while IGRT dose and comorbidities were not significant. Conclusions: IGRT plays a key role in reducing antibiotic-requiring infections in patients with primary immunodeficiency. Regular monitoring and individualized dose adjustments may help optimize outcomes. Further prospective studies are needed to confirm these findings.
1 November 2025 in Allergologia et Immunopathologia
Following bee stings, multiple case reports have described the onset of autoimmune-related conditions, including myasthenia gravis, nephrotic syndrome, Henoch-Schönlein purpura, myocardial infarction, cerebrovascular events, and localized alopecia, typically within a few days, indicating that bee venom may play a role in triggering autoimmunity. We report a rare case of total alopecia occurring within ten days after a bee sting. While the literature includes one prior case of total alopecia following bee sting-induced anaphylaxis, our case is distinct in that the patient developed total alopecia in the absence of any hypersensitivity reactions, suggesting a potential immunomodulatory or exacerbating effect of the bee sting on the immune system.
Background/Objectives: This study aimed to determine bacteria that grow in spontaneous ascites infection and their antibiotic susceptibility. Materials and Methods: A total of 291 cases of cirrhosis-related ascites were retrospectively analyzed between January 2007 and September 2015. Simple ascites, spontaneous ascites infection, spontaneous bacterial peritonitis, and culture results were recorded. Due to increasing antibiotic resistance, theoretically appropriate antibiotics were paired, and their susceptibility was evaluated in order to review our empirical antibiotic choices and evaluate new empirical treatment options. Results: In all cultures, 48.1% were Gram-positive cocci and 50.6% were Gram-negative bacilli. Multidrug-resistant bacteria grew in 16 cultures (22.2%). The most common bacterium was Escherichia coli, and the second most common bacteria were coagulase-negative staphylococci (CoNS). According to all culture data, the rate of antibiotic susceptibility was third- and fourth-generation cephalosporins between 76.4 and 68%, 68% for ampicillin-sulbactam, 81.8% for piperacillin-tazobactam, 66% for ciprofloxacin, 71% for levofloxacin, 30% for tetracycline, and 45% for penicillin. Beta-lactam group antibiotic susceptibility of CoNS was 25% for penicillin and 53% for ampicillin-sulbactam; 52% had methicillin resistance. The rate of resistance to quinolones was 35%. Multidrug resistance was detected in 40% of CoNS (eight cases). When theoretically appropriate antibiotics were paired, combination therapy increased the susceptibility rates. Conclusions: The increase in Gram-positive infections and resistance to other antibiotic groups indicates empirical antibiotic selection based on local microbial culture results and antibiotic susceptibility. Our results are crucial to allowing for more rational and successful use of antibiotics.
23 September 2026 in Central European Journal of Immunology
Introduction: Common variable immunodeficiency (CVID) presents with diverse clinical and immunological manifestations. This study aimed to investigate the relationships between clinical phenotypes and immunological profiles in an adult CVID cohort. Material and Methods: We retrospectively evaluated demographic and clinical features, infectious/non-infectious complications, immunological parameters, and flow cytometric findings in 32 adult patients (aged ≥ 18 years; 14 female, 18 male) diagnosed with CVID. Results: Based on clinical phenotypes and organ system involvement, three clusters were identified: Cluster 1 (n = 10, 31.2%) was characterized by dominant infectious phenotype; Cluster 2 (n = 8, 25.0%) featured infectious manifestations but lacked lymphoproliferation; allergic conditions were relatively more common; and Cluster 3 (n = 14, 43.8%) was distinguished by dominant autoimmune features and lymphoproliferation. The most frequently observed cluster in our patient cohort was Cluster 3. The most significant predictors in the clustering analysis were lymphoproliferation, autoimmunity, and infection. The percentage of CD4+CD45RO+ cells was significantly higher in patients without infections, whereas the percentage of CD8+CD45RO+ cells was higher in those with infections (p = 0.007 and 0.003, respectively). Among patients with autoimmunity, CD8+CD45RO+ percentages were lower and CD21lowCD38low B cell populations were higher compared to those without autoimmunity (p = 0.005 and p = 0.047, respectively). Conclusions: This study highlights infection, autoimmunity, and lymphoproliferation as prominent phenotypic features in CVID and reveals distinct immune cell profiles among these phenotypes. These findings may provide valuable guidance for improving diagnostic processes and patient management in CVID.
Background: Biologic therapies can control severe asthma and may modify its natural history beyond symptom control. However, step‐down is not standardized, and its safety has not been clearly established. Methods: This single‐center retrospective cohort study reviewed adults with severe asthma on biologics (January 2019–May 2024). Step‐down strategies (discontinuation of add‐on therapy and/or inhaled corticosteroid [ICS] dose reduction) were described, success rates calculated, and clinical characteristics compared between groups with and without step‐down. Results: Fifty‐one patients were included, of whom 10 (19.6%) received omalizumab, 34 (66.7%) mepolizumab, and 7 (13.7%) benralizumab. After excluding 6 patients unsuitable for step‐down assessment, 45 patients were compared. Step‐down was attempted in 21 of these (46.7%) and succeeded in 17 (81.0%), defined as no systemic corticosteroid use, emergency visit, loss of control (ACT < 20), or exacerbation through the last visit. The most frequent interventions were ICS dose reduction ( n = 7, 33.3%) and montelukast discontinuation ( n = 7, 33.3%). Biologics had been received for a mean of 42.6 ± 14.0 months, and the reduced regimen was maintained for 8.15 ± 5.23 months. Compared with the non–step‐down group, the step‐down group had a higher proportion of males ( p = 0.005) and longer follow‐up ( p = 0.007). Conclusion: In this real‐world cohort, step‐down was feasible and appeared safe, with most patients maintaining the reduced regimen without deterioration in control or exacerbations. These findings support supervised treatment minimization in carefully selected, well‐controlled patients, adding real‐world evidence to a limited literature.